NCT00735904

Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer

Phase 2 Trial Of AG-013736 As First-Line Treatment For Patients With Squamous Non-Small Cell Lung Cancer Receiving Treatment With Cisplatin And Gemcitabine

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate whether AG-013736 when combined with cisplatin and gemcitabine shows activity and is safe in patients with squamous type of non-small cell lung cancer

Conditions

• Carcinoma, Non-Small-Cell Lung (NSCLC)

Interventions

Type	Name	Description
DRUG	AG-013736	AG-013736 5 mg tablets orally, twice daily, until disease progression
DRUG	gemcitabine	200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m\^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles
DRUG	cisplatin	1mg/ml solution or as lyophilized powder, to be administered as 80 mg/m\^2 IV infusion on Day 1 of 21-day cycle. For a maximum of 6 cycles

Timeline

• Start date: 2008-12-01
• Primary completion: 2011-11-01
• Completion: 2011-11-01
• First posted: 2008-08-15
• Last updated: 2013-01-03
• Results posted: 2013-01-03

Locations

10 sites across 4 countries: Poland, Romania, South Africa, Ukraine